439117-39-2

Basic information

• Product Name: [2-(AMINOMETHYL)-5-CHLOROPHENYL]METHANOL
• Synonyms: [2-(AMINOMETHYL)-5-CHLOROPHENYL]METHANOL
• CAS NO: 439117-39-2
• Molecular Formula: C₈H₁₀ClNO
• Molecular Weight: 171.6241
• Mol File: 439117-39-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [2-(AMINOMETHYL)-5-CHLOROPHENYL]METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: [2-(AMINOMETHYL)-5-CHLOROPHENYL]METHANOL(439117-39-2)
• EPA Substance Registry System: [2-(AMINOMETHYL)-5-CHLOROPHENYL]METHANOL(439117-39-2)

Safety Data

• Hazardous Substances Data: 439117-39-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
[2-(AMINOMETHYL)-5-CHLOROPHENYL]METHANOL is used as a key intermediate in the pharmaceutical industry for the synthesis of various complex molecules. Its unique structure allows for the creation of a wide range of therapeutic agents.
Used in Agrochemical Synthesis:
In the agrochemical industry, [2-(AMINOMETHYL)-5-CHLOROPHENYL]METHANOL is utilized as a starting material for the development of new compounds with potential applications in agriculture, such as pesticides and herbicides.
Used in Biological Research:
[2-(AMINOMETHYL)-5-CHLOROPHENYL]METHANOL is also used in biological research as a compound of interest for studying its potential biological activities and therapeutic applications, which may lead to the discovery of new treatments for various diseases and conditions.
Safety and Handling:
It is crucial to handle and use [2-(AMINOMETHYL)-5-CHLOROPHENYL]METHANOL safely and in accordance with proper guidelines and regulations to minimize any potential risks associated with its use.

Upstream product

• 56961-26-3 2-bromo-3-chlorobenzoic acid 
• 21739-93-5 2-bromo-5-chlorobenzoic acid 
• 494210-98-9 methyl 5-chloro-2-[((trifluoromethyl)sulfonyl)oxy]benzoate 
• 439117-38-1 methyl 5-chloro-2-cyanobenzoate 

Downstream Products

• 928754-18-1 (4-chloro-2-chloromethyl-benzyl)-carbamic acid tert-butyl ester 
• 439117-43-8 N-fluorenylmethoxycarbonyl-L-prolyl-2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzylamide 
• 439117-45-0 [4-Chloro-2-({[(S)-1-((R)-2-hydroxy-3,3-dimethyl-butyryl)-pyrrolidine-2-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 439117-50-7 [4-Chloro-2-({[(S)-1-((R)-2-hydroxy-3-methyl-butyryl)-pyrrolidine-2-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 486394-64-3 [4-Chloro-2-({[(S)-1-((R)-2-hydroxy-3,3-dimethyl-butyryl)-azetidine-2-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 439117-44-9 (S)-tert-butyl 4-chloro-2-((pyrrolidine-2-carboxamido)methyl)benzylcarbamate 
• 439118-00-0 (2-{[(azetidine-2-carbonyl)-amino]-methyl}-4-chloro-benzyl)-carbamic acid tert-butyl ester 
• 439116-15-1 2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzylamine 
• 439117-41-6 1-azidomethyl-2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzene 
• 439117-40-5 tert-butyl 4-chloro-2-(hydroxymethyl)benzylcarbamate 

Relevant articles and documents

PYRROLIDINE THROMBIN INHIBITORS

Compounds of the invention, which may be useful in inhibiting thrombin and associated thrombotic occlusions, have the following structure: (I) or a pharmaceutically acceptable salt thereof, wherein R is a heterocycle or -(CR4R5)1-2NH2 , wherein R4 and R5,

Stereoselective synthesis of a potent thrombin inhibitor by a novel P2-P3 lactone ring opening

The concise synthesis of a potent thrombin inhibitor was accomplished by a mild lactone aminolysis between an orthogonally protected bis-benzylic amine and a diastereomerically pure lactone. The lactone was synthesized by the condensation of L-proline met

Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability

Modification of lead compound 1 by reducing lipophilicity in the P3 group produced a series of low molecular weight thrombin inhibitors with excellent potency in functional assays, metabolic stability, and oral bioavailability. These modifications led to

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, e.g. 1-(3(S)-Cyclopropyl-2(R)-hydroxybutanoyl)azetidine-2(S)-N-(2-aminomethyl-5-chlorobenzyl)carboxamide, and 1-(3-Cyclopropyl-3-methyl-2(R)-hydroxybutanoyl)azetidine-2(S)-N-(2-aminomethyl-5-chlorobenzyl)carboxamide.

Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position

Thrombin inhibitors incorporating o-aminoalkylbenzylamides in the P1 position were designed, synthesized and found to have enhanced potency and selectivity in several different structural classes. X-ray crystallographic analysis of compound 24 bound in the α-thrombin-hirugen complex provides an explanation for these unanticipated results.

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and treating blood coagulation and cardiovascular disorders and have the following structure: wherein R3 is hydrogen or halogen, and u is N or CH.

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, e.g. where R3 is —CH2NH2, —CH2CH2NH2, or —CH2NHC(O)OC(CH3)3.